Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026. The company ...
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results